Google
CCCC Stock Price & Analysis — C4 Therapeutics Inc (Healthcare >> Biotechnology)
CCCC FAQ
What is CCCC's ROE?
C4 Therapeutics Inc reports a Return on Equity (ROE) of -44.31%.
What is CCCC's dividend yield?
C4 Therapeutics Inc offers a dividend yield of 0.00%.
What is CCCC's Quality Score?
Our AI rates CCCC's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CCCC?
Our AI Timing Score for CCCC is 55 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CCCC belong to?
C4 Therapeutics Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
CCCC AI Analysis Summary
Our AI summary for CCCC: C4 Therapeutics Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -44.31%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 55/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 3.50
Price
0.02
(0.57%)
Day Change
|
|
|---|
CCCC, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 85 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 3.50 |
| PBV / Sector |
1.64 / 44,219.29
|
| Earning Per Share | -0.94 |
| PE / Sector |
N/A / 19.28
|
| PEG or PE/Growth / Sector |
N/A / 1.23
|
| Average 1M Daily Value |
11.40 M
GREAT
|
| Average 1W Daily Value |
7.30 M
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-04 08:01:17 |
| Symbol | CCCC |
| Name | C4 THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 110.57 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 384.77 / 9,645.64 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 490 Arsenal Way, Watertown, MA, United States, 02472
Phone: 617 231 0700
Website: https://www.c4therapeutics.com
Employees: 104
Sector: Healthcare >> Biotechnology
Description: C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap